Loading market dashboard
Maison Solutions Inc. Class A Common Stock
MSSConsumer DefensiveNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in
MONTEREY PARK, CA / ACCESS Newswire / May 25, 2026 / Maison Solutions Inc. (NASDAQ:MSS) ("Maison Solutions" or the "Company"), a specialty grocery retailer offering traditional Asian food and merchandise to customers in the United States, today announced that Alexandria Marie Lopez, Chief Financial Officer, has been named a 2026 nominee for the LA Executive Awards, presented by LA Times Studios and the Los Angeles Times Media Group. The LA Executive Forum & Leadership Awards brings together executives and entrepreneurs from the Los Angeles region for networking, strategic discussions, and recognition.
MONTEREY PARK, CA / ACCESS Newswire / May 12, 2026 / Maison Solutions Inc. (NASDAQ:MSS) ("Maison Solutions" or the "Company"), a specialty grocery retailer offering traditional Asian food and merchandise to U.S. consumers, today announced that on May 11, 2026, it received written notification from The Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC stating that the Company has regained compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Accordingly, the Company's Class A common stock will continue to be listed and traded on the Nasdaq Capital Market.
SAN FRANCISCO and SUZHOU, China, May 10, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted a third Breakthrough Therapy Designation (BTD) to its first-in-class PD-1/IL-2α-bias bispecific fusion protein, IBI363, in combination with bevacizumab, for the treatment of patients with advanced microsatellite stable or proficient mismatch repair (MSS/pMMR) colorectal cancer (CRC) who have failed at least two prior lines of standard therapy. A Phase III clinical trial is about to initiate in China for this indication in the near term.
2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs. Historical 4–6 Month Benchmark Company Engaged with FDA to Support Potential Accelerated Approval Pathway in 2L RAS-Mutant MSS mCRC SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown to activate innate immune-sensing pathways, today announced new durability data in metastatic colorectal cancer (“mCRC”), demonstrating meaningful and sustained clinical benefit in patients with RAS-mutant, microsatellite-stable (“MSS”) disease.
MONTEREY PARK, CA / ACCESS Newswire / April 29, 2026 / Maison Solutions Inc. (NASDAQ:MSS) today provided notice of proposed settlement of derivative actions and settlement hearing. UNITED STATES DISTRICT COURT CENTRAL DISTRICT OF CALIFORNIA IN RE MAISON SOLUTIONS INC.
MONTEREY PARK, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Maison Solutions Inc. (NASDAQ:MSS) today provided notice of proposed settlement of derivative actions and settlement hearing.
MONTEREY PARK, CA / ACCESS Newswire / April 22, 2026 / Maison Solutions Inc. (NASDAQ:MSS) ("Maison Solutions" or the "Company"), a specialty grocery retailer offering traditional Asian food and merchandise to U.S. consumers, today announces that, as previously approved by the stockholders of the Company, it will implement a 1-for-10 reverse stock split of its outstanding shares of Class A common stock, effective on April 24, 2026, at 12:01 a.m. Eastern Time (the "Reverse Split").
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Maison Solutions (NASDAQ: MSS - Get Free Report) and Alto Ingredients (NASDAQ: ALTO - Get Free Report) are both small-cap consumer discretionary companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability. Valuation and Earnings This table compares
Advantage Solutions (NASDAQ: ADV - Get Free Report) and Maison Solutions (NASDAQ: MSS - Get Free Report) are both small-cap consumer discretionary companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability. Institutional and Insider Ownership 49.8% of
MONTEREY PARK, CA / ACCESS Newswire / March 17, 2026 / Maison Solutions Inc. (NASDAQ:MSS) ("Maison" or the "Company"), a specialty grocery retailer offering traditional Asian food and merchandise to U.S. consumers, today announced financial results for its fiscal third quarter ended January 31, 2026. For the quarter, the Company incurred a net loss of $5.2 million.
Maison Solutions (NASDAQ: MSS - Get Free Report) is anticipated to release its results before the market opens on Monday, March 16th. Analysts expect Maison Solutions to post earnings of $0.02 per share and revenue of $33.10 million for the quarter. Maison Solutions (NASDAQ: MSS - Get Free Report) last announced its quarterly earnings data on Monday,
